R&D – Talk Bio

Actionable Insights Powered by AI

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Pfizer Taps Novartis Veteran Jeffrey Legos to Lead Oncology R&D Efforts

3 months ago talkbio0Tagged Cancer Research, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Pfizer, R&D

Pfizer, Jeffrey Legos, oncology, R&D, leadership, cancer research, pharmaceutical industry

AstraZeneca Invests $570M in Canadian Expansion, Creating 700 New Jobs

3 months ago talkbio0Tagged AstraZeneca, Canadian, Clinical Trials, Drug Industry, expansion, Investments, R&D

AstraZeneca, Canadian expansion, $570M investment, 700 new jobs, life sciences, R&D, clinical trials, pharmaceutical industry

Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, digital transformation, Drug Development, generative, Google Cloud, Pharmaceutical Research, R&D, Servier, therapeutic solutions

Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.

Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations

4 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, Candid, partnerships, R&D, T-Lymphocyte, TCEs

Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships

Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp

4 months ago talkbio0Tagged Biotechnology, Chief Medical Officer, Dietmar Berger, Drug Industry, Gilead Sciences, R&D, reSET (device)

Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry

Empowering Women in Life Sciences: 2024’s Trailblazers in Biopharma R&D

5 months ago talkbio0Tagged 2024, Biological Science Disciplines, Biopharma, Fiercest, Gender, Health care facility, innovation, R&D, Women

Women in Life Sciences, Biopharma R&D, 2024’s Fiercest Women, Gender Balance, Innovation in Healthcare

Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development

5 months ago talkbio0Tagged Boshoff, Changing, Chris, Leadership, Mikael, Neoplasms, Pfizer, President brand of dental material, R&D, Research and Development, Scientific Officer

Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D

Alto Neuroscience’s Mid-Stage Depression Trial Fails, Casting Doubts on Neuropsychiatry R&D Strategy

6 months ago talkbio0Tagged Alto, ALTO-100, Biological Markers, Clinical Failure, depression trial, Neuroscience discipline, R&D

Alto Neuroscience, depression trial, neuropsychiatry R&D, ALTO-100, biomarker strategy, clinical failure